Journal of Clinical Oncology
Articles in this Issue
Exploring transcriptomic regulation of the tissue-associated microbiome in oncogenic progression of colorectal cancer.
3609 Background: The association between the tissue microbiome and colorectal cancer (CRC) etiology continues to be explored, and it has been proposed tha...
Molecular landscape and therapeutic vulnerability of RRAS- and RRAS2-mutant solid tumors.
3065 Background: The RRAS subfamily of small GTPases shares considerable sequence homology with the canonical RAS oncoproteins KRAS ,...
SECN-15: A novel treatment option for patients with checkpoint inhibitor–resistant tumors by targeting Neuropilin-1 with antisense oligonucleotides.
2580 Background: SECN-15 is a high-affinity antisense oligonucleotide (ASO) targeting Neuropilin-1 (NRP1), a transmembrane protein that exerts a variety o...
Identifying breast cancer diagnosis stages in high-risk patients using a population genetic screening program at a community health system.
e22521 Background: Endeavor Health implemented a family-health-history screening tool called the Genetic Wellness Assessment (GWA) in routine primary care...
A phase I dose-escalation study to evaluate safety and feasibility of neoadjuvant camrelizumab with palbociclib for the treatment of resectable esophageal squamous cell carcinoma (ESCC).
e16114 Background: Immune checkpoint inhibitors (ICIs) have enhanced treatment outcomes for patients with esophageal squamous cell carcinoma (ESCC) in bot...
Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic <i>GNAS</i> variants.
3572 Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality, with 20-25% of cases presenting with metastatic disease (mCRC). P...
Racial disparities in 3-year cancer-specific and overall survival for metastatic renal cell carcinoma with sarcomatoid features (msRCC): A retrospective analysis from the SEER database (2010-2020).
e16523 Background: msRCC is an aggressive cancer subtype. However, the impact of racial disparities in this population remains underexplored. This study a...
Uncovering the tumor microenvironment (TME): Exploring survival and immunotherapy (IO) response in cancer of unknown primary (CUP).
4198 Background: Cancer of Unknown Primary (CUP) is a group of rare and heterogeneous metastatic cancers with unidentifiable site of origin at time of dia...
Belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory multiple myeloma: An indirect comparison using patient-level data.
7536 Background: Belantamab mafodotin (belamaf) is being studied in combination with bortezomib + dexamethasone (BVd) or pomalidomide + dexamethasone (BPd...
Amivantamab plus chemotherapy vs chemotherapy in <i>EGFR</i> -mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2.
8639 Background: Amivantamab (ami), an EGFR-MET bispecific antibody with immune cell–directing activity, combined with chemotherapy (chemo) is approved fo...
<i>BRCA1/2</i> and <i>PALB2</i> short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC).
4183 Background: CH results from fitness-enhancing mutations in hematopoietic stem cells. Many CH somatic variants (SVs) are in cancer-associated genes, i...
Neoadjuvant APG-157 monotherapy in patients with locally advanced squamous cell carcinoma of head and neck: A phase IIA, single arm trial.
6087 Background: Newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN) poses significant treatment challenges due to its...
Interactions between polygenic variants and clinical factors as predictors of breast cancer risk in the UK Biobank.
10512 Background: Polygenic risk scores (PRSs) combine information from single-nucleotide polymorphisms (SNPs) across the genome to explain substantial ge...
Second primary malignancy (SPM) in patients (pts) with multiple myeloma (MM) receiving chimeric antigen receptor T-cell (CAR T) therapy or other systemic anticancer therapy (SACT): A comparative study using a real-world database.
7519 Background: Cases of SPM have been reported following CAR T therapy, but comparative studies are scarce. We compared the risk of SPM following CAR T...
GPRC5D and BCMA bi-specific CAR-T: Ex vivo study to simulate early to late-line multiple myeloma (MM) with elevated soluble BCMA.
7538 Background: GPRC5D and BCMA are near-universally expressed on MM cells, with independent target expression and double-negative cells relatively rare....
Efficacy of BTI615 on malignant cells expansion and bone marrow fibrosis in a myelofibrosis mice model.
6572 Background: Due to the limitation of Janus kinase inhibitors and allogeneic transplant, critical unmet needs are remained in myelofibrosis (MF) patie...
Phase I trial of MK2 inhibitor in combination with mFOLFIRINOX for untreated metastatic pancreatic ductal adenocarcinoma.
TPS4233 Background: Zunsemetinib (also known as ATI-450) is an investigational small molecule inhibitor targeting MAPK-Activated Protein Kinase (MAPKAPK2,...
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: A report by the RANO resect group.
2001 Background: The effects of resection in IDH-mutant grade 2 gliomas remain controversial since terminology for extent of resection was inconsistently...
Factors associated with readmission to index vs. non-index hospitals after major cancer surgery: Does centralization play a role?
11073 Background: While centralization of complex cancer surgery at regional referral centers improves perioperative outcomes, many vulnerable patients fa...
Impact of the Q61H mutational subtype on the response to standard first line treatment in patients with colon adenocarcinoma with KRAS mutation.
e15603 Background: In the systemic treatment of metastatic colorectal adenocarcinoma (mCRC), the RAS/RAF/MEK/ERK MAPK pathway is a strong negative predict...
Efficacy and safety from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: Analyses at an extended median follow-up.
7528 Background: Talquetamab (Tal) is the first and only approved anti-GPRC5D bispecific antibody (BsAb) for relapsed/refr...
Recurrence risk prediction model in HER2-positive early breast cancer after HER2-targeted therapy.
1035 Background: HER2-positive breast cancer patients treated with adjuvant targeted therapy, including trastuzumab or pertuzumab have demonstrated improv...
Influence of tumor infiltrating lymphocytes (TIL) monotherapy on persistent clinical and immunological responses in Asian metastatic melanoma patients with specific CD8+ TIL proportions: A phase I trial.
9548 Background: TIL therapy, as one of the most promising adaptive cellular immunotherapy, has shown success in metastatic melanoma, with a median overal...
Epidemiological characteristics affecting cholangiocarcinoma patients with and without hepatitis B&C: A retrospective analysis.
e16471 Background: Cholangiocarcinoma is a rare, aggressive cancer with high mortality rates. These tumors are often diagnosed in the later stages; resect...
Treatment patterns and survival outcomes in US veterans aged ≥80 with newly diagnosed diffuse large B-cell lymphoma.
e19072 Background: The optimal management of older patients with cancer remains a significant unmet need. This is exemplified in Diffuse Large B-Cell Lymp...